Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

GSK under Luke Miels is a different company than GSK under Emma Walmsley. Miels told us in February that oncology may offer "the most tempting targets" and that GSK would pursue drugs that outperform established blockbusters rather than build from scratch. The Nuvalent deal delivers exactly that thesis. Zidesamtinib and neladalkib are potential best-in-class ROS1 and ALK inhibitors designed to overcome resistance mutations that limit current therapies (Pfizer's Xalkori, Roche's Alecensa). Both are already under FDA review. If both are approved this year, GSK will have two new oncology launches in 2027, providing near-term revenue growth to complement its cardiovascular build (Baxfendy) and cardiometabolic pipeline (SiranBio ALK7). Bank of America called it "a bold move from new CEO in oncology, adding two imminent growth drivers." Reuters described it as "marking a strategic shift." Bloomberg said GSK is trying to "rebuild its oncology franchise." The net investment of approximately $9.4B (after Nuvalent's cash) is expected to be accretive to sales and core operating profit in 2027. The deal also adds an early-stage HER2 lung cancer drug and several preclinical programs, giving GSK a platform in targeted lung cancer beyond the initial two assets. 👉 Read Full Analysis

🔮 What To Watch

🚀 Top Story

GSK Acquires Nuvalent for $10.6B in Its Largest Deal in Over a Decade GSK | NUVL

What Happened: GSK announced on June 9 a definitive agreement to acquire Nuvalent for approximately $10.6B in an all-cash tender offer at $124 per share, a 40% premium to Nuvalent's last closing price and a 26% premium to the 30-day average. Net investment is approximately $9.4B after accounting for Nuvalent's cash. Close expected Q3 2026, funded by new and existing debt facilities plus cash.

The Assets:

Zidesamtinib (ROS1 inhibitor): Potential best-in-class, under FDA review for ROS1-positive NSCLC. Designed to overcome resistance mutations that limit current ROS1 inhibitors. 2026 PDUFA expected.

Neladalkib (ALK inhibitor): Potential best-in-class, under FDA review for ALK-positive NSCLC. Designed to address resistance to current ALK inhibitors (Alecensa, Lorbrena). 2026 PDUFA expected.

HER2 lung cancer drug: Early-stage. Expands GSK's lung cancer platform beyond ROS1 and ALK.

Preclinical programs: Additional oncology candidates providing pipeline depth.

Executive Impact: This is the first major acquisition under CEO Luke Miels, who took the helm last year with a mandate to rebuild GSK's oncology franchise. Bank of America: "We see the deal as a bold move from new CEO in oncology, adding two imminent growth drivers." Reuters: "marking a strategic shift under new CEO Luke Miels as the British company steps up its focus on oncology." STAT noted GSK has been trying to "be more aggressive with its oncology strategy." Analysts said the deal could help offset GSK's expected HIV patent cliff if the lung cancer approvals come on time. GSK targets exceeding GBP 40B in sales by 2031. The deal is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029 inclusive of synergies.

🏢 Corporate & Business Developments

Incyte Acquires Vega Therapeutics for $1.25B INCY

Incyte announced a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25B, according to The Pharma Letter. The deal expands Incyte's pipeline. Specific indication details were not immediately available.

🔬 Clinical & Research Updates

Celcuity's Gedatolisib Doubles PFS in Breast Cancer but Stock Drops 25% CELC

Celcuity's gedatolisib doubled progression-free survival versus standard of care in PIK3CA-mutated advanced breast cancer at ASCO, but shares dropped more than 25% on Tuesday, according to BioSpace. One investigator said the drug could "establish a new standard of care." However, investors viewed the absolute magnitude of PFS improvement as insufficient relative to expectations. The disconnect between clinical significance and investor expectations illustrates a recurring dynamic in oncology: doubling a poor baseline (for example, 4 months to 8 months) may be statistically meaningful but commercially underwhelming.

📅 The Week Ahead

In under six months as CEO, Luke Miels has executed a clear strategic pivot:

Oncology: GSK/Nuvalent ($10.6B, two late-stage lung cancer drugs). GSK/IDRx KIT inhibitor ASCO data (potential Gleevec successor in GIST). Ris-Rez ADC (B7-H3-targeting) for lung cancer expansion.

Cardiovascular/Cardiometabolic: GSK/SiranBio ALK7 siRNA ($1B, obesity-adjacent cardiometabolic fat reduction). Pipeline includes FGF21 analog for MASH (Phase 3 ready).

Vaccines: Shingrix franchise ($1.4B Q1, +20%). Existing HIV and respiratory portfolios.

The thesis: GSK is building a diversified pharma company across oncology, cardiovascular/cardiometabolic, and vaccines. The Nuvalent deal is the oncology anchor. SiranBio is the cardiometabolic bet. Shingrix funds the build.

Miels told reporters: "I think it's going to be very crowded" in GLP-1, explaining why GSK chose the "downstream effects of obesity" strategy rather than competing on weight loss directly. The Nuvalent deal adds oncology to this positioning, giving GSK growth drivers across multiple therapeutic areas without direct exposure to the GLP-1 price war.

💊 ROS1 and ALK: Why Best-in-Class Matters

ROS1 rearrangements occur in approximately 1-2% of NSCLC patients. ALK rearrangements occur in approximately 3-5%. Both are treatable with targeted kinase inhibitors, but current therapies (crizotinib, alectinib, lorlatinib) face resistance mutations that limit duration of response.

Zidesamtinib (ROS1) and neladalkib (ALK) are designed to bind with higher potency and selectivity, overcoming known resistance mutations. If approved, they would give oncologists a next-line option for patients who progress on current therapies and potentially a better first-line option based on broader mutation coverage.

The commercial opportunity is meaningful despite the small mutation-defined populations. Current ALK and ROS1 inhibitors generate billions collectively (Pfizer's Xalkori + Lorbrena, Roche's Alecensa). Best-in-class replacements can capture significant share rapidly, as demonstrated by lorlatinib's displacement of crizotinib.

📊 M&A Running Total: June 2026

Major deals announced in 2026:

Total 2026 M&A now exceeds $115B (CNBC reported $106B through early June; GSK/Nuvalent adds $10.6B).

🎯 Catalyst Calendar: June 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →